BioSpace News Archive

Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology

Technavio announced its latest market research report titled global ear infection treatment market 2019-2023.

Lens Parameters Expanded by Nearly 60 percent, Providing Eye Care Professionals the Broadest Offering Among All Daily Disposable Toric Lenses

Enteris BioPharma, Inc., provided a review of its 2019 key business achievements and development activities as the company anticipates multiple growth opportunities during 2020 involving its industry-leading Peptelligence® oral peptide delivery technology.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 7:30 am PT, or 10:30 am ET, in San Francisco, California.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of $40-$50 million in cumulative total contract value (TCV) and has expanded its personalized ctDNA minimal residual disease (MRD) and monitoring intellectual property portfolio with 8 newly allowed or issued patents in 2019.

Gerard (Jerry) A. Vitti, president and CEO of Healthcare Financial Inc. (HFI), a firm that connects vulnerable populations with public benefit programs, will serve on the Editorial Advisory Council of FierceHealthcare, a digital platform that publishes top-notch content on a range of health-related verticals.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has signed agreements to acquire Parcus Medical,

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference

Glass Lewis States “[W]e Believe the Current Proposal Warrants Investor Support”; Provides Detailed Critique of Alpha’s “Murky” Financing Proposal – Noting Alpha’s “Abdication of Transparency”